Skip to main content
. 2001 Mar;158(3):1145–1160. doi: 10.1016/S0002-9440(10)64062-X

Figure 4.

Figure 4.

In situ hybridization illustrating cellular VPF/VEGF mRNA expression at various times after injection of adeno-vpf/vegf into the ears of athymic mice. a and b: At 18 hours, scattered cells in dermis (some indicated by black arrows) express large amounts of VPF/VEGF mRNA. b: Some of the positive cells are immediately adjacent to a mother vessel (m). c–e: At 4 days, numerous VPF/VEGF-positive cells are observed deep in the dermis just above the ear cartilage (cart), the location where GBs most commonly form. Note strongly positive cells immediately adjacent to mother vessels (m). e: VPF/VEGF-expressing cells are in immediate proximity to a primitive GB (arrows), developing in a deep dermal mother vessel (m) adjacent to ear cartilage (cart). f: Eight-day reaction illustrating VPF/VEGF-expressing cells in centers of several maturing GBs (one indicated with an arrow). g: At 14 days, several VPF/VEGF-expressing cells persist within GBs (brackets) but average intensity is somewhat reduced in comparison with 8 days. h: Further reduction in numbers and staining intensity of VPF/VEGF-expressing cells at 21 days. A residual positive cell is placed centrally within a GB (brackets). i: By 35 days, VPF/VEGF mRNA was no longer detectably expressed and GBs had begun to devolve into normal microvessels. d and f: Phase contrast microscopy; all others, bright field. Scale bars, 25 μm.